3SBio Inc. Announces Unaudited Second Quarter 20...(th above is preliminary andsubject to ad...),Health

Date:8/11/2009

th above is preliminary and subject to adjustments and modifications. The audited financial statements and related notes are to be included in our annual report on Form 20-F for the year ending December 31, 2009. Adjustments and modifications to the financial statements may be identified during the course of the audit work, which could result in significant differences from this preliminary unaudited financial information.

Currency Convenience Translation

For the convenience of readers, certain RMB amounts have been translated into US dollars at the rate of RMB6.8302 to US$1.00, the noon buying rate for US dollars in effect on June 30, 2009 for cable transfers of RMB per US dollar as certified for customs purposes by the Federal Reserve Bank of New York. A rate of 6.8591 was used for comparative purposes as of June 30, 2008.

About 3SBio Inc.

3SBio Inc. is a leading, fully integrated biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, primarily in China. For more information, please visit 3SBio on the web at http://www.3sbio.com .

Safe Harbor Statement

Certain statements in the disclosures of 3SBio, Inc. (the "Company" or "3SBio") for the second quarter, 2009 ("Disclosures") that are not purely historical in nature constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. The Disclosures include the press release, the conference call and any accompanying materials, and any other information issued, released or publicized by the Company with respect to the second quarter of 2009. These forward-looking statements include, but may not be limited to, discussions and statements regarding revenue guidance, product development, regulatory approval process, plant completion, production capacity, cap
'/>"/>

SOURCE 3SBio Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25
Related medicine news :

1. 3SBio Inc. to Report 2009 Second Quarter Earnings on August 11, 2009
2. 3SBio Inc. Announces Unaudited First Quarter 2009 Results
3. 3SBio Inc. Files for SFDA Approval for TPIAO Label Extension for the Treatment of ITP
4. 3SBio Inc. Announces Filing of Annual Report on Form 20-F
5. 3SBio Inc. to Present at The CIBC World Markets 18th Annual Healthcare Conference
6. Jazz Pharmaceuticals Announces Second Quarter 2009 Financial Results
7. Webmedx Announces That CEO Sean Carroll Has Been Appointed to the AHIMA Foundation Board of Directors
8. Epix Pharmaceuticals, Inc. Announces PRX-07034 Therapeutics - CNS Phase 2 Will be Part of the Intellectual Property Offered for Sale at the September 30, 2009 Auction
9. Leading Medical Developer Announces Plans for Texoma Medical Plaza
10. iMedX Announces Investment of $13M From RFE Investment Partners
11. Health Market Science Announces Commercial Release of CompleteSpend V2.5